|
Dr. Lau has a varied background including academic medicine, financial management and executive management of pharmaceutical/biotech companies. Dr. Lau is a managing director of Roth Capital Partners. Previously he was the Chairman and CEO of Ribapharm Inc. where he led the second largest IPO in the 20 years of biotechnology history. Prior he was Senior VP and Head of R&D at ICN Pharmaceuticals. Prior he was Senior Director of Antiviral Therapy at Schering-Plough. Dr. Lau was involved with a number of successful Investigational New Drugs (INDs) and New Drug Applications (NDAs). He has published over 200 scientific papers, over 40 reviews/editorials in leading scientific journals, and edited two books. Dr. Lau also serves as a member of the Board of Directors of Vioquest (OTCBB: VQPH) and Chairman of the Board of Kinex Pharmaceuticals. Dr. Lau is a Fellow of the Royal College of Physicians of United Kingdom and received his medical degree and doctoral degree from the University of Hong Kong. | 